Skip to content
BiologicalX

Comparison

Alpha-GPC vs Omega-3 (EPA/DHA)

Side-by-side of Alpha-GPC and Omega-3 (EPA/DHA). Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Alpha-GPC

  • Choline donor supplement, roughly 40% choline by weight; crosses blood-brain barrier efficiently
  • Replicated small gains in attention and reaction time at 300 to 600 mg in healthy adults
  • Standard prescription cognitive medication in much of Europe (Gliatilin) at 1,200 mg/day for vascular cognitive impairment
  • ASCOMALVA trial (n=210) showed cognitive preservation when added to donepezil over 24 months
  • Increases acute power output (~14%, single trial) and transient growth hormone secretion at 600 mg
  • TMAO production raises a contested cardiovascular concern at chronic high doses

Omega-3 (EPA/DHA)

  • Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
  • REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
  • Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
  • Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
  • Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
  • Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state

Side-by-side

Attribute Alpha-GPC Omega-3 (EPA/DHA)
Category supplement supplement
Also known as L-Alpha glycerylphosphorylcholine, choline alfoscerate, GPC, alpha-glyceryl phosphorylcholine fish oil, EPA, DHA, marine omega-3
Half-life (hr) 4 48
Typical dose (mg) 600 2000
Dosing frequency 1 to 3 times daily 1 to 2 times daily with food
Routes oral oral
Onset (hr) 1 4
Peak (hr) 2 12
Molecular weight 257.22 302.45
Molecular formula C8H20NO6P C20H30O2 (EPA); C22H32O2 (DHA)
Mechanism Hydrolyzed to free choline and glycerophosphate after absorption; choline supports acetylcholine and phosphatidylcholine synthesis in CNS. Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function.
Legal status Dietary supplement (US); prescription medication in much of Europe Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia
WADA status allowed allowed
DEA / Rx OTC supplement Not scheduled
Pregnancy Insufficient data; choline generally recommended in pregnancy Recommended at 200 to 600 mg DHA/day for fetal development
CAS 28319-77-9 10417-94-4
PubChem CID 71920 446284
Wikidata Q411478 Q207688

Safety profile

Alpha-GPC

Common side effects

  • mild GI upset
  • headache
  • dizziness
  • occasional insomnia with evening dosing

Contraindications

  • established cardiovascular disease (TMAO concern)
  • concurrent strong anticholinergic therapy

Interactions

  • anticholinergic medications: partial mutual antagonism(minor)
  • cholinesterase inhibitors (donepezil): additive cholinergic effect, basis for ASCOMALVA protocol(minor)
  • scopolamine: partial counteraction of anticholinergic effect(minor)

Omega-3 (EPA/DHA)

Common side effects

  • fishy aftertaste
  • eructation (fish burps)
  • mild dyspepsia
  • loose stools at high doses

Contraindications

  • fish allergy (use algal omega-3 alternative)
  • active bleeding disorders
  • scheduled surgery (discontinue 5-7 days prior)

Interactions

  • warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
  • aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
  • statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
  • antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)

Which Should You Take?

Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Alpha-GPC is the right call when one of the conditionals below applies.

  • If your priority is athletic performance, pick Alpha-GPC.
  • If your priority is choline supply, pick Alpha-GPC.
  • If your priority is cardiovascular health, pick Omega-3 (EPA/DHA).
  • If your priority is healthspan extension, pick Omega-3 (EPA/DHA).

Edge case: Half-lives differ materially (Alpha-GPC ~4 hr vs Omega-3 (EPA/DHA) ~48 hr). Omega-3 (EPA/DHA) reaches steady state faster; Alpha-GPC is easier to dial in if tolerability is uncertain.

Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Alpha-GPC only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Alpha-GPC and Omega-3 (EPA/DHA)?

Alpha-GPC and Omega-3 (EPA/DHA) differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Alpha-GPC or Omega-3 (EPA/DHA)?

Alpha-GPC half-life is 4 hours; Omega-3 (EPA/DHA) half-life is 48 hours.

Can you stack Alpha-GPC with Omega-3 (EPA/DHA)?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper